Fenamates as Potential Therapeutics for Neurodegenerative Disorders.
Jaunetta Hill1, Nasser H Zawia1,2,3
1Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA.
Cells
|April 3, 2021
Summary
Drug repurposing offers hope for neurodegenerative diseases. Fenamates, particularly tolfenamic acid, show promise for treating conditions like Alzheimer's disease by modulating key molecular pathways.
Area of Science:
- Neuroscience
- Pharmacology
- Drug Discovery
Background:
- Neurodegenerative diseases lack effective treatments.
- Drug repurposing is a vital strategy for developing new therapies.
- Fenamates are a class of drugs with potential therapeutic applications.
Purpose of the Study:
- To review existing research on fenamates for neurodegenerative diseases.
- To focus on tolfenamic acid and its role in Alzheimer's disease.
- To explore the molecular mechanisms targeted by fenamates.
Main Methods:
- Comprehensive literature review of fenamate research.
- Analysis of studies on neurodegenerative disease models.
- Examination of molecular pathway data.
Main Results:
- Fenamates demonstrate efficacy in preclinical models of neurodegeneration.
- Tolfenamic acid shows particular promise for Alzheimer's disease.
- Multiple molecular pathways are identified as targets for fenamate action.
Conclusions:
- Fenamates represent a promising avenue for drug repurposing in neurodegenerative disorders.
- Further research into tolfenamic acid is warranted for Alzheimer's disease treatment.
- Understanding fenamate-modulated pathways can guide future therapeutic development.
Keywords:
Alzheimer’s diseaseNSAIDfenamateflufenamic acidmeclofenamic acidmefenamic acidneurodegenerativetolfenamic acidMore Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
536
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
536
01:14Antiepileptic Drugs: Glutamate Antagonists
657
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
657
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
295
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
295
01:29Drugs Affecting Neurotransmitter Synthesis
1.8K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.8K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.3K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.3K
01:26Alzheimer's Disease: Overview
1.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.0K